This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Injectable contraceptives

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Injectable hormonal contraceptives (1) are slow release, long lasting progesterone preparations administered intramuscularly at intervals from 1 to 6 months. Common preparations include medroxyprogesterone acetate and norethisterone enanthate.

The main disadvantages are due to the progesterone. Many experience some degree of menstrual disturbance; in some, this can be irregular uterine bleeding which may be heavy and prolonged whilst others may experience amenorrhoea.

Injectable contraception however, may be particularly suited:

  • following rubella vaccination in the puerperium
  • while awaiting for vasectomy to be proven in a partner
  • in women with a chaotic lifestyle where taking an oral contraceptive regularly is difficult

Injectable hormonal contraception is 96% to 99% effective for pregnancy prevention (typical to perfect use) (2)

References:

  1. Progestogen-only Injectable Contraception Clinical Guidance. Faculty of Sexual and Reproductive Healthcare (December 2014, amended 2020)
  2. Hatcher R. Contraceptive technology. 21st ed. New York: Ardent Media; 2018.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.